Baricitinib for systemic lupus erythematosus: not enough, or not enough evidence?

Patoulias, Dimitrios; Dimosiari, Athina; Dimitroulas, Theodoros

doi:10.55563/clinexprheumatol/0of42a

Search citation statements

Order By: Relevance

Paper Sections

Select...

Jak Inhibition In Sle: From Murine Models To Human Studies1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 55 Analysis of the above-mentioned studies indicates that while neither the 2mg nor the 4 mg baricitinib dose correlated with a significant increase in the odds of achieving an LLDAS response, the 4 mg dose was associated with a significant increase in the odds of an SRI-4 response, compared to placebo. 56 …”

Section: Jak Inhibition In Sle: From Murine Models To Human Studiesmentioning

confidence: 99%

JAK Inhibition as a Potential Treatment Target in Systemic Lupus Erythematosus

Moysidou,

Dara

2024

MJR

View full text Add to dashboard Cite

Janus kinase (JAK)/signal transducers and activators of transcription (STATs) are a group of molecules responsible for signal transduction of multiple cytokines and growth factors in different cell types, involved in the maintenance of immune tolerance. Thus, the dysregulation of this pathway plays a crucial role in the pathogenesis of multiple autoimmune, inflammatory, and allergic diseases and is an attractive treatment target. JAK inhibitors (JAKinibs) have been approved in the treatment of multiple autoimmune diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (SPA). In SLE, there is a plethora of ongoing trials evaluating their efficacy, with tofacitinib, baricitinib and deucravacitinib showing promising results, without major safety concerns. In this review, we will discuss the rationale of targeting JAKinibs in SLE and summarize the clinical data of efficacy and safety of JAKinibs in SLE patients.

show abstract

Section: Jak Inhibition In Sle: From Murine Models To Human Studiesmentioning

confidence: 99%